Table 2.
Total number of comparisons identified, and numbers identified by zinc vs. no zinc comparisons available in all identified studies by age group and outcome 1.
| Ages 2 | Serum or Plasma Copper | Serum Ceruloplasmin | ESOD | Serum Ferritin | Hemoglobin | Serum Transferrin Receptor | Lipids | Dose Ranges of Studies by Age 3 (mg) |
|---|---|---|---|---|---|---|---|---|
| 0–5 months | 1 | 0 | 0 | 2 | 1 | 0 | 1 | 4–5 |
| 6–12 months | 11 | 0 | 1 | 20 | 25 | 6 | 1 | 2.3–10 |
| 1–3 years | 3 | 1 | 2 | 11 | 18 | 2 | 0 | 0.9–20 |
| 4–6 years | 5 | 0 | 0 | 5 | 9 | 0 | 1 | 1.2–21.4 |
| 7+ years | 3 | 4 | 3 | 1 | 3 | 0 | 1 | 2.8–17.1 |
| Total | 23 | 5 | 6 | 39 | 56 | 8 | 4 | 0.9–21.4 |
Original to this manuscript: 1 Sorting is subjective, using the mean initial age and the time period in which most of the intervention took place (for example, if the mean initial age was 4 months and the study lasted 6 months, the study was counted in the 6–12-month age range); 44 total studies provided these 141 comparisons (Tables S1–S7). 2 Age ranges are similar to those used to develop RI and UL recommendations (Table 1). 3 Daily supplemental doses of zinc provided in the studies in this review, by mean initial age (Tables S1–S7).